Rhythm Pharmaceuticals, INC 8-K filings

Rhythm Pharmaceuticals announced robust second quarter 2026 financial results, driven by strong IMCIVREE sales and encouraging preliminary data from its RM-718 Phase 2 trial.

Rhythm Pharmaceuticals shareholders re-elected two directors and ratified the appointment of Ernst & Young LLP at the 2026 Annual Meeting.

Rhythm Pharmaceuticals announced positive interim six-month data from its Phase 2 trial of setmelanotide in Prader-Willi Syndrome patients, showing significant improvements in BMI, body composition, and hyperphagia.

Rhythm Pharmaceuticals reported first quarter 2026 financial results, highlighting strong initial uptake for IMCIVREE in acquired hypothalamic obesity and progress in global regulatory approvals.

Rhythm Pharmaceuticals has appointed Kimberly J. Popovits as a new director and accepted the resignation of Edward T. Mathers from its Board of Directors.

Rhythm Pharmaceuticals announced a positive opinion from the European Medicines Agency's CHMP for IMCIVREE to treat acquired hypothalamic obesity.

Rhythm Pharmaceuticals announced FDA approval for an expanded indication of IMCIVREE (setmelanotide) to treat acquired hypothalamic obesity in adults and pediatric patients aged 4 years and older.

Rhythm Pharmaceuticals announced that its Phase 3 EMANATE trial for setmelanotide did not meet primary endpoints in four substudies, though post hoc analyses showed significant BMI reductions in two patient populations.

Rhythm Pharmaceuticals announced additional positive Phase 3 data for setmelanotide in acquired hypothalamic obesity, reinforcing its potential as a first-in-class therapy.

Rhythm Pharmaceuticals announced robust fourth quarter and full year 2025 financial results, driven by IMCIVREE sales growth and significant progress in its clinical pipeline.

Rhythm Pharmaceuticals announced preliminary unaudited Q4 and full-year 2025 net product revenues for IMCIVREE, showing significant growth, alongside upcoming clinical and regulatory milestones.

Dr. Camille L. Bedrosian has resigned from Rhythm Pharmaceuticals' Board of Directors, effective immediately on December 16, 2025.

Rhythm Pharmaceuticals announced positive preliminary Phase 2 results for setmelanotide in Prader-Willi syndrome, showing reductions in BMI and hyperphagia, and plans to advance to a Phase 3 trial.

Rhythm Pharmaceuticals announced the FDA extended the review period for its supplemental New Drug Application for IMCIVREE for acquired hypothalamic obesity by three months to March 20, 2026.

Rhythm Pharmaceuticals reported strong third-quarter 2025 revenue growth for IMCIVREE, driven by Bardet-Biedl syndrome sales, and anticipates an FDA decision for acquired hypothalamic obesity by December 20, 2025.

Rhythm Pharmaceuticals announced robust second quarter 2025 financial results, including significant revenue growth and positive clinical trial data for its lead assets, alongside a successful capital raise.

Rhythm Pharmaceuticals, Inc. announced the full exercise of an underwriting option, raising approximately $188.7 million in net proceeds from a public offering of 2,367,647 shares of common stock at $85.00 per share, bolstering its financial runway for at least 24 months.

Rhythm Pharmaceuticals announced positive topline results from its Phase 2 trial of bivamelagon, an oral MC4R agonist, showing statistically significant and clinically meaningful BMI reductions in patients with acquired hypothalamic obesity.

Rhythm Pharmaceuticals, Inc. announced the results of its Annual Meeting of Stockholders, including the approval of an amendment to its Certificate of Incorporation to exculpate officers from certain fiduciary duty liabilities and the election of two Class II Directors.

Rhythm Pharmaceuticals announced positive first quarter 2025 financial results, highlighted by strong IMCIVREE sales and progress in their setmelanotide and bivamelagon clinical programs.

Rhythm Pharmaceuticals announces positive topline results from its Phase 3 TRANSCEND trial, demonstrating a statistically significant and clinically meaningful reduction in BMI with setmelanotide in patients with acquired hypothalamic obesity.

Rhythm Pharmaceuticals regains full rights to IMCIVREE in China by terminating its licensing agreement with RareStone Group Ltd.

Rhythm Pharmaceuticals announces the date for its 2025 annual meeting of stockholders and deadlines for stockholder proposals and director nominations.

Rhythm Pharmaceuticals announces positive Q4 2024 financial results, driven by IMCIVREE sales, and provides updates on its clinical programs and financial outlook.

Rhythm Pharmaceuticals reports strong preliminary unaudited net product revenues for 2024 and provides updates on its clinical development pipeline.

Rhythm Pharmaceuticals announced a 14% sequential increase in global IMCIVREE sales and positive clinical data for hypothalamic obesity, with key milestones expected in the near future.

Rhythm Pharmaceuticals successfully held its annual meeting, electing three Class I directors and approving the ratification of the accounting firm, executive compensation, and the equity incentive plan.

Rhythm Pharmaceuticals announced a 51% increase in second-quarter revenue year-over-year, driven by global sales of IMCIVREE, and provided updates on clinical trials and regulatory submissions.

Rhythm Pharmaceuticals has filed a prospectus supplement to allow certain stockholders to resell up to 3,124,995 shares of common stock.

Rhythm Pharmaceuticals has postponed its 2024 annual meeting of stockholders from June 18 to September 18 due to a technical error in the record date used for the broker search.